.Planet Health And Wellness Institution. Being overweight as well as over weight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Ailment Danger Factor Cooperation. Worldwide styles in undersized and weight problems coming from 1990 to 2022: a pooled evaluation of 3663 population-representative researches with 222 million youngsters, teenagers, as well as grownups. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google Scholaru00c2.Global Problem Disease Collaborators. Global, local, and also national problem of diabetic issues from 1990 to 2021, along with forecasts of prevalence to 2050: a methodical analysis for the Global Burden of Health Condition Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google.com Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & World Renal Day Steering Board. Weight problems and kidney ailment: hidden consequences of the epidemic. Kidney Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
An organized customer review and meta-analysis suggests weight problems predicts onset of constant kidney health condition in the general populace. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google Scholaru00c2.Jiang, Z. et cetera. Being overweight and chronic renal condition.
Are actually. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Venue, J. E., perform Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Weight problems, kidney problems as well as high blood pressure: mechanistic web links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Renal Ailment: Improving Worldwide Outcomes CKD The Office Team.
KDIGO 2024 Medical Process Tip for the evaluation and management of constant renal health condition. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Kidney Disease: Improving International End Results Diabetes Mellitus Work Group. KDIGO 2022 Scientific Method Guideline for diabetic issues administration in chronic kidney disease. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et cetera.
Early modification in albuminuria with canagliflozin predicts kidney as well as heart end results: a message hoc evaluation coming from the CREDENCE test. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.de Zeeuw, D. et al. Proteinuria, an aim at for renoprotection in people with kind 2 diabetic person nephropathy: sessions from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et cetera. Is a decrease in albuminuria linked with renal as well as heart security?
A message hoc review of the ALTITUDE trial. Diabetic issues Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic person renal condition: a customer review of their renal as well as heart defense. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 and also the kidney: from anatomy to pharmacology as well as results in diabetes mellitus.
Nat. Rev. Nephrol.
Thirteen, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et cetera. Semaglutide and also cardio end results in people with kind 2 diabetes. N.
Engl. J. Medication.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide and also cardiovascular end results in weight problems without diabetes. N.
Engl. J. Med.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Perkovic, V. et cetera.
Effects of semaglutide on constant kidney ailment in patients along with style 2 diabetes. N. Engl.
J. Med. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et al.
Long-lasting renal outcomes of semaglutide in weight problems and heart attack in the SELECT trial. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Results of semaglutide on albuminuria and renal functionality in folks with obese or even weight problems with or even without kind 2 diabetes mellitus: preliminary analysis from the measure 1, 2, and 3 tests.
Diabetic issues Treatment 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Shaman, A. M.
et al. Result of the glucagon-like peptide-1 receptor agonists semaglutide and also liraglutide on kidney results in patients with style 2 diabetic issues: pooled analysis of SUSTAIN 6 and LEADER. Flow 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Apperloo, E. M. et al.
Effect of semaglutide on renal function throughout various degrees of baseline HbA1c, high blood pressure, body system weight and albuminuria in SUSTAIN 6 and leader 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et cetera. Dulaglutide versus blood insulin glargine in individuals along with type 2 diabetic issues as well as moderate-to-severe chronic renal condition (AWARD-7): a multicentre, open-label, randomised test.
Lancet Diabetes Mellitus Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Change in albuminuria as a surrogate endpoint for progression of kidney illness: a meta-analysis of treatment effects in randomised professional trials. Lancet Diabetic Issues Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Mann, J. F. E.
et al. Effects of semaglutide along with as well as without concomitant SGLT2 prevention use in attendees with kind 2 diabetes and also severe kidney ailment in the FLOW test. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and also safety outcomes with GLP-1 receptor agonists alone and in blend with SGLT2 preventions in kind 2 diabetic issues: a systematic evaluation and also meta-analysis.
Flow https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et al. Efficiency as well as protection of SGLT2 preventions along with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised regulated trials. Lancet Diabetic Issues Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Results of tirzepatide versus the hormone insulin glargine on renal results in style 2 diabetic issues in the SURPASS-4 test: post-hoc study of an open-label, randomised, stage 3 test.
Lancet Diabetes Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et al. Body body weight and eGFR throughout dulaglutide procedure in kind 2 diabetes mellitus and also moderate-to-severe severe renal condition (AWARD-7).
Diabetic issues Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et cetera. Results of tirzepatide versus insulin glargine on cystatin c-based renal feature: a SURPASS-4 message hoc study. Diabetes Care 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Diabetic Issues Treatment (American Diabetes Affiliation, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et cetera. Effects of bariatric surgical treatment on kidney functionality in obese clients: a systematic examine and also meta study.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The results of bariatric surgery on kidney results: a methodical analysis and also meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google Scholaru00c2.Clerte, M.
et cetera. The gauged glomerular purification rate (mGFR) prior to and also 6 months after bariatric surgical procedure: an aviator research study. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google Scholaru00c2.Fawaz, S.
et al. Adiponectin minimizes glomerular endothelial glycocalyx disturbance and repairs glomerular obstacle feature in a computer mouse design of type 2 diabetes mellitus. Diabetes mellitus 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Kidney hyperfiltration related to diabetic issues mellitus and also obesity in individual health condition. Realm J.
Diabetes 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Chagnac, A. & Friedman, A.
N. Assessing albuminuria in people with weight problems: difficulties of the urinary albumin-creatinine ratio. Kidney Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in grownups with obese or even excessive weight.
N. Engl. J.
Medication. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Levey, A.
S. et cetera. A more correct procedure to approximate glomerular purification rate from cream creatinine: a brand-new prediction formula.
Adjustment of Diet in Renal Illness Study Group. Ann. Intern.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS technique for iohexol resolution in individual EDTA as well as lithium-heparin blood, individual pee and also in goat- and also swine EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K. R. et cetera.
Efficacy and also protection of aldosterone synthase hangup with and without empagliflozin for chronic renal disease: a randomised, regulated, period 2 trial. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.de Zeeuw, D.
et cetera. Efficacy of an unfamiliar inhibitor of vascular adhesion protein-1 in minimizing albuminuria in clients with diabetic renal disease (CD): a randomised, placebo-controlled, period 2 test. Lancet Diabetes Mellitus Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in combo with dapagliflozin compared with dapagliflozin in individuals with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, stage 2b, medical trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Result of avenciguat on albuminuria in individuals with CKD: pair of randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et al.
Sparsentan in clients along with IgA nephropathy: a prespecified interim evaluation due to a randomised, double-blind, active-controlled clinical test. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.